A recent survey conducted by Piper Sandler shows most of the 101 veterinarians it polled expect the prices they charge and the volume of patients they see to mostly hold up in the months ahead.
While Piper Sandler "modestly" trimmed earnings estimates for 2024 for animal health-care companies Zoetis, Idexx Laboratories and Elanco Animal Health , Westenberg said Zoetis' products performed well in the survey.
Solensia rang up $30 million in sales last year, but the opportunity for Librela is even bigger, according to the analyst.
ZTS YTD mountain Even with the recent pullback in Zoetis stock, shares are up more than 18% year to date.
In the Piper Sandler survey, few vets said they would pick the company's Credelio Quattro as their primary parasiticide when it is released.
Persons:
Piper Sandler, David Westenberg, Westenberg, Librela, Solensia, Zoetis, FactSet, Quattro
Organizations:
Idexx Laboratories, U.S . Food, Drug Administration, Elanco
Locations:
parasiticides, U.S